Houston, we have lift off! 🚀
Last week,
@ValoHealth announced it acquired Courier Therapeutics, a
#JLABSTMC company developing a protein therapeutics platform with the potential to improve
#cancer immunotherapy. Congrats to the Courier team on this milestone! ⬇️
Valo is excited to announce our acquisition of Courier Therapeutics!
"We are enthusiastic about Courier's proprietary cell-targeting technology because we believe it positions Valo to create a new frontier in cancer-immunotherapies,"
@DavidBerry26.
on.wsj.com/3zJDHDR @WSJ